https://mpnasia.onionyeh.com/sessions/2026-01-registration/2026-09-22T07:00:18+00:00https://mpnasia.onionyeh.com/sessions/2026-02-opening-remarks/2026-09-22T07:00:18+00:00https://mpnasia.onionyeh.com/sessions/2026-03-mpn-updates-and-the-evolution-of-the-diseases/2026-09-22T07:00:18+00:00https://mpnasia.onionyeh.com/sessions/2026-04-the-myeloproliferative-neoplasms-acquired-genetics-and-a-big-surprise/2026-09-22T07:00:18+00:00https://mpnasia.onionyeh.com/sessions/2026-05-inflammation-as-disease-driver-and-therapeutic-target-in-mpns/2026-09-22T07:00:18+00:00https://mpnasia.onionyeh.com/sessions/2026-06-targeting-the-mpn-stem-cell-and-molecular-response-as-a-surrogate-for-survival/2026-09-22T07:00:18+00:00https://mpnasia.onionyeh.com/sessions/2026-07-panel-discussion/2026-09-22T07:00:18+00:00https://mpnasia.onionyeh.com/sessions/2026-08-break/2026-09-22T07:00:18+00:00https://mpnasia.onionyeh.com/sessions/2026-09-modern-management-of-myelofibrosis/2026-09-22T07:00:18+00:00https://mpnasia.onionyeh.com/sessions/2026-10-clinical-and-molecular-genetic-characterization-of-myelofibrosis/2026-09-22T07:00:18+00:00https://mpnasia.onionyeh.com/sessions/2026-11-early-intervention-in-myelofibrosis/2026-09-22T07:00:18+00:00https://mpnasia.onionyeh.com/sessions/2026-12-panel-discussion/2026-09-22T07:00:18+00:00https://mpnasia.onionyeh.com/sessions/2026-13-lunch/2026-09-22T07:00:19+00:00https://mpnasia.onionyeh.com/sessions/2026-14-understanding-the-biology-of-polycythemia-vera-and-changes-in-treatment-approaches/2026-09-22T07:00:19+00:00https://mpnasia.onionyeh.com/sessions/2026-15-a-new-era-in-polythemia-vera-early-intervention-for-disease-management/2026-09-22T07:00:19+00:00https://mpnasia.onionyeh.com/sessions/2026-16-ropeg-ifn-%ce%b1-selectively-suppresses-jak2-v617f-clones-in-pv-treatment/2026-09-22T07:00:19+00:00https://mpnasia.onionyeh.com/sessions/2026-17-predictors-of-treatment-response-in-pv-treated-with-ropeginterferon-alfa-2b/2026-09-22T07:00:19+00:00https://mpnasia.onionyeh.com/sessions/2026-18-panel-discussion/2026-09-22T07:00:19+00:00https://mpnasia.onionyeh.com/sessions/2026-19-break/2026-09-22T07:00:19+00:00https://mpnasia.onionyeh.com/sessions/2026-20-therapeutic-advances-clinical-trials-in-et/2026-09-22T07:00:19+00:00https://mpnasia.onionyeh.com/sessions/2026-21-real-world-experience-prospective-ropeginterferon-alfa-2b-therapy-in-pv-et/2026-09-22T07:00:19+00:00https://mpnasia.onionyeh.com/sessions/2026-22-advancements-in-essential-thrombocythemia-management/2026-09-22T07:00:19+00:00https://mpnasia.onionyeh.com/sessions/2026-23-from-dosing-strategy-to-clinical-benefit-rethinking-interferon-use-patterns-to-optimize-efficacy-and-safety/2026-09-22T07:00:19+00:00https://mpnasia.onionyeh.com/sessions/2026-24-break/2026-09-22T07:00:19+00:00https://mpnasia.onionyeh.com/sessions/2026-25-myelodysplastic-myeloproliferative-neoplasms-with-ring-sideroblasts-and-thrombocytosis-mds-mpn-rs-t/2026-09-22T07:00:19+00:00https://mpnasia.onionyeh.com/sessions/2026-26-metformin-alleviates-side-effects-and-supports-the-resumption-of-interferon-therapy-in-pv-and-et/2026-09-22T07:00:19+00:00https://mpnasia.onionyeh.com/sessions/2026-27-myeloproliferative-neoplasm-subtype-impacts-risk-of-incident-osteoporosis-and-osteoporotic-fractures/2026-09-22T07:00:19+00:00https://mpnasia.onionyeh.com/sessions/2026-28-panel-discussion/2026-09-22T07:00:19+00:00https://mpnasia.onionyeh.com/sessions/2026-29-closing-remarks/2026-09-22T07:00:19+00:00